**CURRICULUM VITAE**

**University of Alabama at Birmingham School of Medicine**

Date: August 24, 2020

**PERSONAL INFORMATION**

Name: Jeffrey David Lebensburger

Citizenship: United States of America

Home Address: 3608 Brookwood Rd. Mountain Brook, AL 35223

Phone: 205 638-5429

Business Address: 1600 7th Avenue South, Lowder Bldg 512; Birmingham, AL 35233

Phone: 205 638-9285

Fax: 205 975-1941

Email: jlebensburger@peds.uab.edu

**RANK/TITLE**:

Department: Pediatrics, UAB Division of Pediatrics

Associate Professor, UAB Division of Pediatric Hematology Oncology

Director, Pediatric Hematology Section.

Co-Director, UAB Comprehensive Lifespan Sickle Cell Center

**HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS:**

2015-Present: Associate Professor of Pediatrics, University of Alabama at Birmingham

2017-Present: Adjunct Associate Professor of Pediatrics, Meharry Medical College

2017-Present: Associate Scientist, Nephrology Research &Training Center, University of

Alabama at Birmingham

2009- 2015: Assistant Professor of Pediatrics, University of Alabama at Birmingham

**EDUCATION:**

2010-2016 Master of Science in Public Health University of Alabama at Birmingham

1999-2003 Doctor of Osteopathic Medicine Nova Southeastern University

1993-1997 Bachelor of Arts University of Pennsylvania

**LICENSURE:**

2009-Present Alabama Osteopathic Medical License

2006-2009 Tennessee Osteopathic Medical License

**BOARD CERTIFICATION:**

2011-Present American Board of Pediatric Hematology Oncology

2006-Present American Board of Pediatrics

**POSTDOCTORAL TRAINING:**

2006-2009 Fellow, Pediatric Hematology Oncology St. Jude Children's Research Hospital 2003-2006 Intern and Resident, Pediatrics Arnold Palmer Hospital for Children

**ACADEMIC APPOINTMENTS:**

2015-present Associate Professor University of Alabama at Birmingham

2017-Present: Adjunct Associate Professor of Pediatrics, Meharry Medical College

2009-2015 Assistant Professor University of Alabama at Birmingham

**AWARDS/HONORS:**

2017-present Castle Connolly Top Doctors

2016-2017 Department of Pediatrics Excellence in Teaching Award

2015-present Best Doctors in America®

2014-2015 Department of Pediatrics Excellence in Teaching Award

2015 Scholar Award, American Society of Hematology

2015 Top Doctors, B-metro Magazine

2013 Fellow, National Heart Lung Blood Institute. Office of Behavioral Social Science Research. Institute on Randomized Behavioral Clinical Trials.

2012-2013 Department of Pediatrics Excellence in Teaching Award

2010 Scholar, American Society of Hematology, Clinical Research Training Institute

2006 Teaching Resident Award, Arnold Palmer Hospital for Children

2003 Dean’s Award, Nova Southeastern University College of Osteopathic Medicine

2003 Psi Sigma Alpha Member

2001-2002 Presidential Knight, Nova Southeastern University

2000-2001 Student of the Year, Nova Southeastern University

**PROFESSIONAL SOCIETIES:**

2018-Present American Society of Nephrology

2016-Present Society for Pediatric Research

2016-Present Delta Omega Honorary Public Health Society

2006-Present American Society of Hematology

2006-Present American Society of Pediatric Hematology Oncology

**COUNCILS AND COMMITTEES:**

National

2019-2022 American Society of Hematology.

Clinical Research Training Institute

 Co-Director

Steering Subcommittee, Curriculum Representative

Description: The Clinical Research Training Institute competitively invites 20 international junior faculty/fellows interested in clinical research careers to a one-week training institute and year-long mentorship program. Twenty faculty are selected to participate in this program as lecturers and mentors based on expertise in clinical research. I served as faculty for three years and was then nominated and elected co-Director by faculty members. As co-Director, I am responsible for organizing the study section, selecting faculty, developing curriculum, and leading this program.

2020-2022 American Society of Hematology

Research Collaborative Sickle Cell Disease Clinical Trial Network

Member, Scientific Review Subcommittee

Description: The American Society of Hematology developed a Clinical Trials Network to improve access to sickle cell clinical trials for all academic institutions. The Scientific review committee consists of 12 experts tasked with establishing research priorities for sickle cell clinical trials and selecting research studies for the network.

2020-present NIH/NHLBI Cure Sickle Cell Initiative

Cardiopulmonary Renal Panel Member

Description: The NIH is dedicated to ensuring the highest rigor for curative sickle cell research studies. I was selected to lead their initiative to develop guidelines for monitoring renal endpoints as a member of the cardiopulmonary renal panel.

2019-present Novartis

 Steering Committee for STEADFAST trial

Description: Novartis is conducting an international randomized clinical trial of Crizanlizumab for renal outcomes. I was selected as one of seven international experts in sickle cell kidney research to design this study as part of the steering committee.

2018- 2019 American Society of Hematology/Food and Drug Administration

Sickle Cell Disease Clinical Trial Endpoints Workshop

Chair, End Organ Considerations Panel

Description: ASH and FDA developed a workshop to determine appropriate endpoints for future clinical trials seeking FDA approval. I was selected to chair a panel of six experts in organ complications from sickle cell disease. We developed guidelines for monitoring organ complications of sickle cell disease in future clinical studies.

2017- 2019 American Society of Hematology

Clinical Practice Guidelines on Sickle Cell Disease.

Panel member, Cardiopulmonary and Kidney Disease

Description: American Society of Hematology developed clinical practice

guidelines for the management of sickle cell disease. I served as an expert in renal disease for this panel.

2017-present Sickle Cell Clinical Research and Intervention Program.

St. Jude Children’s Research Hospital.

Chair, Renal Working Group

Description: St. Jude Children’s Research Hospital is conducting the largest prospective cohort study for pediatric and adult sickle cell patients. I was selected by the PI to chair the renal working group as an external expert in the field.

2016-2019 NHLBI/NIH BABY HUG Follow-Up II

Publication Committee

2012-2019 NHLBI/NIH BABY HUG Follow-Up II

Steering Committee

Description: Baby HUG Follow-Up II is a NIH sponsored follow-up study evaluating long-term benefits of hydroxyurea therapy. I was selected by the study leadership to the publication and steering committees.

Intramural

2019 University of Alabama at Birmingham, Department of Pediatrics

Director. Fellows Research Round Table

2018- Present University of Alabama at Birmingham, Department of Pediatrics

Teaching Faculty. Fellows Research Round Table

2018 University of Alabama at Birmingham, Pediatric Hematology Oncology Division

Director Search Committee

2017- Present UAB Nephrology Research and Training Center

 Research Scientist

2017-Present UAB Graduate School

 Adjunct Associate Professor

2016 CCTS Pilot Development Committee, Dr. Timmy Lee

2015 CCTS Nascent Panel Committee, Dr. Ahmed Zaky

**Scientific Review Committees**

Institutional Review Committees:

2016-present UAB Pediatric Science Day Reviewer

2015 Kaul Pediatric Research Institute Reviewer

National Scientific Meeting Abstract Reviewer

2016-2018 Foundation for Sickle Cell Research

2019 American Society of Hematology

National Grant Review Committees:

2020 American Society of Hematology, HONORS Study Section

 Hematology Opportunities for the Next Generation of Research Scientists

2018 NIH/NHLBI. Small Grant Program

NHLBI K01/K08/K23 Recipients (R03).

2016-Present American Society of Hematology

Clinical Research Training Institute Study Section

2017 Patient Centered Outcomes Research Institute

International Grant Review:

2016 French National Research Agency (Agence Natioanle de la Recherce)

Scientific Evaluation Panel

**Moderator**

2019 American Society of Hematology Annual Meeting.

2017 American Society of Hematology Annual Meeting.

2015 Sickle Cell Disease Annual Symposium, Clinical Research Session, Moderator

**Data Safety Monitoring Board**

2018-Present Inhaled Mometasone to Promote Reduction in Vasoocclusive Events (NCT 03758950)

 Member, DSMB

**EDITORIAL BOARD MEMBERSHIPS**

2018- Present Academic Editor, PLOS One

Ad hoc reviewer for:

*Blood, Lancet Hematology, Clinical Journal of the American Society of Nephrology, Pediatrics, Journal of Pediatrics, American Journal of Hematology, Blood Advances, JAHA: Journal of the American Heart Association, Pediatric Blood and Cancer, Clinical Trials, Contemporary Clinical Trials, Journal of Pediatric Hematology and Oncology, American Journal of Human Biology, Pediatrics and Therapeutics, Medical Principles and Practice, International Journal of Nephrology and Renovascular Disease, American Journal of Preventative Medicine*

**MAJOR RESEARCH INTERESTS:**

My research experience has focused on determining the risk factors for the development of sickle cell kidney disease as well as treatments for patients who have developed kidney injury. I also have an interest in the effects of fetal hemoglobin induction and severe anemia on organ damage in infants, children, and adolescents with sickle cell anemia.

**TEACHING EXPERIENCE**

2016-Present Faculty, American Society of Hematology. Clinical Research Training Institute

2016-2017 Phenotyping Human Disease (TMS 702). Lecturer

2011-Present Sickle Cell Anemia Teaching Module for 3rd and 4th year medical students

2012-Present Sickle Cell and Thalassemia Teaching module for 2nd year medical students

2013-Present Hematology Board Review for Pediatric Boards. 1st-3rd year Pediatric residents

1997-1999 8th Grade Science Teacher, University School at Nova Southeastern University

**MAJOR LECTURES AND VISITING PROFESSORSHIPS**

1. “Sickle Cell Kidney Disease in Children”. World Congress of Nephrology. Abu Dhabi, UAE. March 2020 (Cancelled or Postponed due to COVID-19)
2. “Sickle Cell Disease and Renal Risks.” American Society of Pediatric Nephrology Annual Meeting. May 4, 2020. Philadelphia, PA. This invited lecture was postponed due to COVID-19 and given virtually on July 31, 2020.
3. “Sickle Cell Kidney Disease” National Institutes of Health/National Heart, Lung, Blood Institute, 2019 Annual Sickle Cell Research Meeting. Symposium “Organ Damage and Dysfunction in Sickle Cell Disease”. Bethesda, MD. August, 2019
4. “The Answer is the Question” American Society of Hematology, Clinical Research Training Institute. La Jolla, Ca. August 2019
5. “The Answer is the Question” American Society of Hematology, Clinical Research Training Institute. La Jolla, Ca. August 2018
6. “Career Development Panel” American Society of Hematology Clinical Research Training Institute. La Jolla, CA. August, 2017.
7. “Sickle Cell Disease” American Society of Hematology, Highlights of ASH 2017, Miami, FL. 2018
8. “Sickle Cell Nephropathy” Vanderbilt Sickle Cell Research Center, Nashville, TN. February 2017
9. “Risk Factors for Sickle Cell Nephropathy”. Pediatric Hematology Oncology Grand Rounds. University of Texas Southwestern. Dallas, TX. January 2017
10. “Planning for a Career Development Award” Fellow Lecture, University of Texas Southwestern. Dallas, TX. January 2017
11. “Sickle Cell Nephropathy”. St Jude Children’s Research Hospital. Invited Lecture. Memphis, TN. January 2017.
12. “Career Development Panel” American Society of Hematology Clinical Research Training Institute. La Jolla, CA. August, 2016.
13. “Understanding Barriers to Sickle Cell Care from the Patient Perspective.” 4th Annual Advancement in the Care of Pediatric Cancer and Blood Disorder Symposium. October 2013.
14. “Inherited Thrombophilia” Genetic Grand Rounds”. University of Alabama Birmingham December 2009.
15. “Overgrowth Syndromes and AML” St. Jude Leukemia/Lymphoma Grand Rounds, Memphis, TN. May 2007
16. “Polycythemia” St. Jude Leukemia/Lymphoma Grand Rounds, Memphis, TN. April 2007
17. “Hearing Loss in Sickle Cell Disease” St. Jude Leukemia/Lymphoma Grand Rounds, Memphis, TN. December 2006
18. “Post Transplant Lymphoproliferative Disorder” St. Jude Leukemia/Lymphoma Grand Rounds, Memphis, TN. Oct 2007
19. “Familial Hemophagocytic Lymphohistiocytosis” St. Jude Leukemia/Lymphoma Grand Rounds, Memphis, TN. March 2007

**GRANT SUPPORT:**

***Current***

1R01HL153386-01

NIH/NHLBI PI: Lebensburger 06/2020-06/2023

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

The goal of this multicenter study is to develop novel pediatric and adult estimated GFR equations that are validated for sickle cell anemia. In addition, we will test novel approaches for more time efficient procedures for measuring GFR.

K23. Mentored Patient Oriented Research Career Development Award

5K23HL127100

NIH/NHLBI PI: Lebensburger 04/1/2015-03/31/2020

(No cost extension)

Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy

The goal of this project is to develop a cohort (n=200) that will monitor the effect of nocturnal of hypertension on progressive kidney disease. Participants with nocturnal hypertension will be eligible to participate in a feasibility trial of losartan to correct nocturnal hypertension.

R03HL244485-01

 NIH/NHLBI. PI: Lebensburger 09/2018-08/2020

 Acute Kidney Injury During Sickle Cell Crisis

The goal of this project is to prospectively follow patients admitted for pain crisis or acute chest syndrome for the development of acute kidney injury. We hypothesize that an increase in free heme/hemoglobin will stimulate endothelin-1 and promote acute kidney injury.

Patient Centered Outcomes Research Institute

PCORI (Osunkwo) Site PI: Lebensburger 8/1/2017-7/31/22

Comparing Effectiveness of Peer Mentoring versus Structured Education-Based Transition Programming for the Management of Care Transitions in Emerging Adults with Sickle Cell Disease

The major goal of this project is to determine if peer mentoring along standard transition education can improve healthcare utilization outcomes for sickle cell patients during transition from pediatric to adult care as compared to standard transition education alone.

***Past***

Pfizer PI: Lebensburger 01/2017-6/01/2020

US ASPIRE Sickle Cell Disease Research Award Grant

Acute Kidney Injury During Sickle Cell Crises

The goal of this project is to prospectively obtain blood and urine on all patients admitted for Acute Chest Syndrome or Pain Crisis. Patients will be followed for development of Acute Kidney Injury. Urine and blood biomarkers will be obtained to determine if patients can be identified prior to development of clinically defined AKI.

American Society of Hematology PI: Lebensburger 08/2015-08/2018

Scholar Award

 Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy

The goal of this project is to develop a cohort (n=200) that will monitor the effect of abnormal nocturnal blood pressure dipping on progressive kidney disease. Participants with abnormal nocturnal blood pressure dipping will be eligible to participate in a feasibility trial of losartan to correct this abnormality.

R34HL108756 PI: Casella 09/2011-6/2018

NIH/NHLBI

Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children

This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications in young children with sickle cell disease. I participate in operations and executive committee conference calls. I organize and present barriers/facilitators to enrollment analysis at NIH and International Investigator meetings.

Role: Site-Primary Investigator

 NHLBI-HB-12-02PI: NHLBI01/2012 – 09/2017

NHLBI/University of Texas Southwestern at Dallas

BABY HUG Follow-Up Study II: Clinical Sites

The goals of BABY HUG Follow UP Study II are to define more accurately the long-term risks and benefits of early HU treatment of children with sickle cell disease (SCD) and to evaluate organ function, growth and psychosocial development, and the predictive value of biomarkers in persons started on HU at young ages.

Role: Site-Primary Investigator

Kaul Pediatric Research Institute PI: Lebensburger 01/2014-01/2016

 Patient Centered Research to Enhance Transition Education

This is a qualitative research project to understand the stakeholder perspective on adolescent transition. The goal is to develop a technology driven intervention to enhance the education of adolescent patients with SCD about transitioning to an adult care provider.

6096A1-3014-WW. PI: Pfizer 06/2009-04/2013

Wyeth/Pfizer

A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children with Sickle Cell Disease Previously Immunized with 23-valent Pneumococcal Polysaccharide Vaccine.

The goal of this project is to determine the safety, tolerability, and immunogenicity of a 13-valent pneumococcal vaccine in children with sickle cell. This trial will attempt to get FDA approval for this vaccine in patients with sickle cell disease.

Role: Site-Primary Investigator

Kaul Pediatric Research Institute PI: Lebensburger 01/2011-2014

Feasibility Trial of Hydroxyurea for Secondary Silent Cerebral Infarct Prevention

The goal of this single arm feasibility trial is to determine the acceptability of hydroxyurea for secondary silent cerebral infarct progression and to monitor adherence to hydroxyurea for this indication.

Role: Primary Investigator

 T32CA070089

NIH/NCI PI: Kasten 07/2007-06/2009

Ruth L. Kirschstein NRSA Institutional Grant. St. Jude Children’s Research Hospital

The goal of this training grant was to provide support for research during fellowship. The goal of the project was to determine the effect of hydroxyurea therapy in the murine model, specifically whether hydroxyurea therapy in a model which cannot generate fetal hemoglobin could provide organ benefit.

Role: Investigator

**BIBLIOGRAPHY**

**MANUSCRIPTS**

**Manuscripts in Publication (\* denotes Lebensburger as corresponding author)**

1. **Lebensburger J,** Persons DA. “Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease.” *Curr Opin Drug Discov Devel*. 2008 Mar; 11(2):225-32. PMID: 18283610.
2. **Lebensburger J,** Esbenshade A, Blakely M, Hankins J, Wang W. “Biloma and pneumobilia in sickle cell disease.” *Pediatr Blood Cancer.* 2008 Aug; 51(2):288-90. PMID: 18421713.
3. **Lebensburger J,** Ware, R. “50 Years Ago in The Journal of Pediatrics: Pure Red Cell Anemia”. *Journal of Pediatrics*. May 2009. 154(5):676.
4. **Lebensburger J\*,** Katzenstein H, Jenkins JJ, Rodriguez-Galindo C. “Bronchioloalveolar carcinoma as a second malignancy in osteosarcoma survivors.” *Pediatr Blood Cancer.* 2009 Sep; 53(3):499-501. PMID: 19418544.
5. **Lebensburger JD,** Pestina TI, Ware RE, Boyd KL, Persons DA. “Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.”*Haematologica.* 2010 Sep; 95(9):1599-603. PMID: 20378564.
6. **Lebensburger J\*,** Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM. “Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.” Am J Hematol. 2011 May; 86(5):430-2. PMID: 21523807.
7. **Lebensburger JD\*,** Hilliard LM, McGrath TM, Fineberg NS, Howard TH. “Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemia.” J Child Neurol. 2011 Oct;26(10):1260-4. PMID: 21572054.
8. **Lebensburger JD,** Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW. “Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. *Blood.* 2012 Feb 23;119(8):1915-21. PMID: 22130804.
9. **Lebensburger JD\*,** DeBaun MR, Thompson AA. “What is the evidence for using hydroxyurea for secondary stroke prevention?” *American Society of Hematology Education* *Program.* 2011; 2011:440-2. PMID: 22160071.
10. **Lebensburger JD\*,** Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC; BABY HUG Investigators. “Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.” *Pediatr Blood Cancer.* 2012 Oct; 59(4):675-8. PMID: 22190441.
11. **Lebensburger JD\*,** Bemrich-Stolz CJ, Howard TH “Barriers in transition from pediatrics to adult medicine in sickle cell anemia.” *J Blood Med.* 2012; 3:105-12. PMID: 23055784.
12. Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, **Lebensburger J,** Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators. “Impact of hydroxyurea on clinical events in the BABY HUG trial.” *Blood.* 2012 Nov 22; 120(22):4304-10. PMID: 22915643.
13. Yates AM, Dedeken L, Smeltzer MP, **Lebensburger JD**, Wang WC, Robitaille N. “Hydroxyurea treatment of children with hemoglobin SC disease.” *Pediatr Blood Cancer.* 2013 Feb; 60(2):323-5. PMID: 22949140.
14. **Lebensburger JD\*,** Sidonio RF, Debaun MR, Safford MM, Howard TH, Scarinci IC. “Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.” *Pediatr Blood Cancer.* 2013 Aug; 60(8):1333-7. PMID: 23418000.
15. Vogel Smith, E, **Lebensburger, JD**, Hilliard, LM, Kelly, D, Fineberg, N, Bai, S, Howard, T. “Ferritin and Liver Iron Concentration in Predicting Liver Histology in Children with Sickle Cell on Chronic Transfusion”. *Journal of Pediatr Gastroenterology and Nutrition*. 2014 Mar; 58(3): 387-90. PMID: 24553473.
16. Hensler M, Wolfe K, **Lebensburger** **JD**, Nieman J, Barnes M, Nolan W, King A, Madan-Swain A. Social Skills and Executive Function Among Youth with Sickle Cell Disease: A Preliminary Investigation. *Journal of Pediatric Psychology*. 2014 Jun; 39(5):493-500. PMID: 24431467.
17. Williams, C., Hogan Smith, C, Osborn, K., Bemrich-Stolz, C., Hilliard, L., Howard, T., **Lebensburger, JD**. Patient Centered Approach to Designing Sickle Cell Transition Education. *Journal of Pediatric Hematology Oncology.* 2015 Jan;37(1):43-7. PMID:24807007.
18. **Lebensburger, J**\*, Grosse, S., Altice, J., Thierry, J., Ivankova, N. Understanding and Improving Health Education among First Time Parents of Infants with Sickle Cell Anemia in Alabama: A Mixed Methods Approach. *Journal of Pediatric Hematology Oncology.* 2015 Jan;37(1):35-42. PMID: 25072367.
19. De Montalembert M, Abboud MR, Fiquet A, Inati A, **Lebensburger JD**, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA. 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study. Pediatric Blood and Cancer 2015 Aug;62(8):1427-36. PMID: 25810327
20. Grissenauer, C, **Lebensburger, J,** Fisher, W, Hilliard, L, Bemrich-Stolz, C, Howard, T, Johnston, J. Encephaloduroarteriosynangiosis (EDAS) for Treatment of Moyamoya Syndrome in Pediatric Patients with Sickle Cell Disease. *Journal of Neurosurgery: Pediatrics.* 2015 Jul 16 (1):64-73. PMID: 25837886.
21. **Lebensburger,** **J\***, Hilliard, L., Pair, L., Oster, R., Howard, T., Cutter G., Systematic Review of Interventional Sickle Cell Trials Registered in ClinicalTrials.gov. *Clinical Trials*. 2015 Dec;12(6):575-83. PMID: 26085544.
22. **Lebensburger, JD\***, Patel, RJ., Palabindela, P., Bemrich Stolz, CJ., Howard, TH., Hilliard LM. Hydroxyurea Decreases Hospitalizations in Pediatric Patients with HbSC and Hb SB+ Thalassemia. *Journal of Blood Medicine*. 2015 Dec 15;6:285-90. PMID: 26719735.
23. Bemrich Stolz, C.,Halanych, J., Howard, T., Hilliard, L., **Lebensburger, J. “Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease” *International Journal of Hematology and Therapy.*  2015 (1)1. Epub 2015 Sep 6. PMID:26900602.**
24. Hamm, J., Hilliard, L., Howard, T., **Lebensburger, J**. “Maintaining High Level of Care at Satellite Sickle Cell Clinics. *Journal of Health Care for the Poor and Underserved.* 2016 Feb 27(1):280-292.
25. **Lebensburger, J**.\*, Palabindela, P., Howard, T., Feig, D., Aban, I., Askenazi, D. “Prevalence of Acute Kidney Injury During Pediatric Admissions for Acute Chest Syndrome.” *Pediatric Nephrology*. 2016 Aug;31(8):1363-8. PMID: 27011218
26. Oh, J., Hamm, J. Xu, X., Genschmer, K., **Lebensburger, J**., Marques, M., Kerby, J., Pittet, J., Gaggar, A., Zhong, M. Patel, R. Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices. *Redox Biology*. 2016 Oct; 9:167-177. PMID 27566280.
27. Goodwin, E., Partain, P., **Lebensburger, J\***, Fineberg, N., Howard, T. “Elective Cholecystectomy Reduces Morbidity of Cholelithiasis in Pediatric Sickle Cell Disease.” *Pediatric Blood and Cancer*. 2017 Jan; 64 (1)113-120. PMID: 27643455
28. Hamm, J., Rathore, N., Lee, P., LeBlanc, Z., **Lebensburger, J**., Meier, E., Kwiatkowski, J. Cranial Epidural Hematomas: A Case Series and Literature Review of this Rare Complication Associated with Sickle Cell Disease. *Pediatric Blood and Cancer*. 2017 Marc; 64(3). PMID 27618802.
29. Rushton, T., Aban, I., Young, D., Hilliard, L. Howard, T. **Lebensburger, J**.**\*** “Hydroxycarbamide for Sickle Cell Patients with Silent Cerebral Infarcts: Outcomes and Patient Preference.” *British Journal of Haematology*. 2017 Jan 20. PMID: 28107562.
30. Aban, I., Baddam, S., Hilliard, L., Howard, T., Feig, D., **Lebensburger J.\*** “Severe Anemia Early in Life as a Risk Factor for Sickle Cell Kidney Disease.” *Blood*. 2017 Jan 19; 129(3)385-387. PMID:27919909
31. Baddam, S., Aban, I., Hilliard, L., Howard, T., Askenazi, D., **Lebensburger J**.**\*** “Acute Kidney Injury During Pediatric Sickle Cell Vas0-Occlusive Pain Crisis”. *Pediatric Nephrology*. 2017 Aug; 32 (8) 1451-1456. PMID: 28238158
32. Baddam, S. Cutter, G., Wolfson, J., Friedman, G., **Lebensburger, J.\*** “Publication Outcomes of Abstracts from the American Society of Hematology Annual Meeting.” *American Journal of Hematology*. 2017 May; 92(5) E81-E83. PMID:28224669
33. **Lebensburger, J.\***, Cutter, G., Howard, T., Muntner, P., Feig, D. “Evaluating Risk Factors for Chronic Kidney Disease in Pediatric Patients with Sickle Cell Anemia.” *Pediatric Nephrology*. 2017 Sep; 32(9): 1565-1573.
34. Leblanc, Z., Vance, C., Payne, J., Zhang, Jie, Hilliard, L., **Lebensburger, J**, Howard, T. “Management of Severe Chronic Pain with Methadone in Pediatric Patients with Sickle Cell Disease.” *Pediatric Blood and Cancer*. 2018 May 11:e27084, PMID:29749702
35. Oakley J, Zahr R, Aban I, Kulkarni V, Patel RP, Hurwitz J, Askenazi D, Hankins J, **Lebensburger** J.**\*** Acute Kidney Injury During Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease. *American Journal of Hematology* 2018 May 14 PMID: 29756409
36. Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, **Lebensburger** J.**\*** Outcomes in Mild to Moderate Thrombocytopenia. *Pediatrics*. 2018 Jun 11 PMID:29891565
37. Hankins JS, Estepp JH, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, **Lebensburger** JD, Adesina O, Chou ST, Zemel BS, Smeltzer MP, Wang WC, Gurney JG. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A Lifespan Cohort Study for Sickle Cell Disease Progression from the Pediatric Stage into Adulthood. *Pediatric Blood and Cancer*. 2018 May 24. PMID:29797644
38. Jason Payne, MD, Inmaculada Aban, PhD, Lee M. Hilliard, MD,Jennifer Madison, CPhT, Christina Bemrich-Stolz, MD, MSPH, Thomas H Howard, MD, Amanda Brandow, DO, MS, Emily Waite, PharmD, **Jeffrey D Lebensburger, DO, MSPH**.**\*** Impact of Early Analgesia on Hospitalization Outcomes for Sickle Cell Pain Crisis. *Pediatric Blood and Cancer*. 2018 Aug27:e272420. PMID: 30151977
39. Krishnaveni Sirigaddi MBBS, Inmaculada Aban, PhD, Amelia Jantz, CRNP, Brandi M. Pernell DNP, Lee M. Hilliard, MD, Smita Bhatia MD, **Jeffrey D Lebensburger DO MSPH**.**\*** Outcomes of Febrile Events in Pediatric Patients with Sickle Cell Anemia. *Pediatric Blood and Cancer.* 2018 Aug 1 e27379. PMID:29891565
40. Hilliard LM, Kulkarni V, Sen B, Caldwell C, Bemrich-Stolz C, Howard TH, Brandow A, Waite E, **Lebensburger JD.\***Red Blood Cell Transfusion Therapy for Sickle Cell Patients with Frequent Painful Events. *Pediatric Blood and Cancer.* 2018 Aug 27:e27423. PMID 30152184
41. Dorjbal B, Stinson JR, Ma CA, Weinreich MA, Miraghazadeh B, Hartberger JM, Frey-Jakobs S, Weidinger S, Moebus L, Franke A, Schäffer AA, Bulashevska A, Fuchs S, Ehl S, Limaye S, Arkwright PD, Briggs TA, Langley C, Bethune C, Whyte AF, Alachkar H, Nejentsev S, DiMaggio T, Nelson CG, Stone KD, Nason M, Brittain EH, Oler AJ, Veltri DP, Leahy TR, Conlon N, Poli MC, Borzutzky A, Cohen JI, Davis J, Lambert MP, Romberg N, Sullivan KE, Paris K, Freeman AF, Lucas L, Chandrasakan S, Savic S, Hambleton S, Patel SY, Jordan MB, Theos A, **Lebensburger** J, Atkinson TP, Torgerson TR, Chinn IK, Milner JD, Grimbacher B, Cook MC, Snow AL. Hypomorphin CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease. *Journal of Allergy Clinical Immunology.* 2018 Aug 28. PMID: 30170123
42. Zahr RS, Hankins JS, Kang G, Li C, Wang WC, **Lebensburger** J, Estepp JH. (co-senior author) Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. *American Journal of Hematology.* 2018 Oct 25. PMID: 30359463.
43. **Lebensburger JD\***, Aban I, Pernell B, Kasztan M, Feig DI, Hilliard LM, Askenazi DJ. Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy. *Am J Hematol*. 2019 Apr;94(4):417-423. PMID 30592084

1. Zahr RS, Rampersaud E, Kang G, Weiss MJ, Wu G, Davis RL, Hankins JS, Estepp JH, **Lebensburger** J**\***. [Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.](https://www.ncbi.nlm.nih.gov/pubmed/30890594) *Haematologica*. 2019 Sep;104(9). PMID:30890594

1. Schlappi, C; Bernstock, J; Ricketts, W; Nix, G.; Poole, C; **Lebensburger, J**; Friedman, G. Roseomonas gilardii Bacteremia in a Patient with HbSB0 thalassemia: Clinical Implications and Literature Review. *Journal of Pediatric Hematology Oncology*. 2020 Jul;42(5). PMID: 30951022
2. Nagalapuram, V, Kulkarni, V, Leach, J, Aban, I, Sirigaddi, K., **Lebensburger, J**, Iyer, P. Effect of sickle cell anemia therapies on the natural history of growth and puberty patterns *Journal of Pediatric Hematology Oncology*. 2019 Nov;41(8). PMID: 30951025
3. Kasztan M, Fox BM, **Lebensburger** JD, Hyndman KA, Speed JS, Pollock JS, Pollock DM. Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice. *Blood Adv.* 2019 May 14;3(9):1460-1475 PMID:31064747
4. Farrell AT, Panepinto J, Desai AA, Kassim AA, **Lebensburger** J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. *Blood Adv.* 2019 Dec 10;3(23):4002-4020. PMID: 31809537
5. Liem RI, Lanzkron S, D Coates T, DeCastro L, Desai AA, Ataga KI, Cohen RT, Haynes J, Osunkwo I, **Lebensburger** JD, Lash JP, Wun T, Verhovsek M, Ontala E, Blaylark R, Alahdab F, Katabi A, Mustafa RA. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood Adv*. 2019 Dec 10;3(23):3867-3897. PMID: 31794601.
6. Kasztan M, Aban I, Hande SP, Pollock DM, **Lebensburger** JD. Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia. *Blood Adv.* 2020 Jan 28;4(2):263-265. PMID: 31951651
7. **Lebensburger JD\***, Gossett J, Zahr R, Wang WC, Ataga KI, Estepp JH, Kang G, Hankins JS. High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. *Haematologica*. 2020 Feb 27. PMID: 32107332
8. Myrick R, Blakemore S, Waite E, Pernell B, Madan-Swain A, Hilliard L, **Lebensburger J\***. Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes. *Pediatric Blood and Cancer*. 2020 Aug 15. PMID:32798305
9. Hood, A., Croby, L., Hanson, E., Shook, L. **Lebensburger, J.,** Madan-Swain, A., Miller, M., Trost, Z. The Influence of Perceived Racial Bias and Health-related Stigma on Quality of Life Among Children with Sickle Cell Disease. *Ethnicity and Health*. Accepted for publication 2020 Aug 23.
10. Nagalapuram, V., McCall, D., Palabindela, P., Howard, T., Bemrich-Stolz, C., **Lebensburger, J**., Hilliard, L., Wilson, H. Outcomes of Isolated Neutropenia Referred to Pediatric Hematology Oncology Clinic*. Pediatrics*. Accepted 2020, July 13.
11. Nourani, A., Rahman, F., Pernell, B., Maddox, M., Hilliard, L., **Lebensburger, J.,** Alishlash, A. Nocturnal Hypoxemia Measured by Polysomnogram is Associated with Acute Chest Syndrome in Pediatric Sickle Cell Disease. Journal of Clinical Sleep Medicine. Accept Sept 22, 2020.

**ORAL ABSTRACT PRESENTATIONS**

1. “Hydroxyurea Treatment Effects in a Sickle Cell Mouse Model” 3rd Annual Sickle Cell Disease Research and Educational Symposium, Feb 2009. *American Journal of Hematology* 2009 E9.

2. “Hydroxyurea Therapy Requires HbF Induction for a Clinical Benefit in a Sickle Cell Mouse Model” American Society of Hematology Annual Meeting Dec 2009. *Blood* 2009 114:817

3. “Coping and Adjustment Among Adolescents with Sickle Cell Disease.” American Society of Hematology Annual Meeting Dec 2014; Blood 2014 124:440*.*

4. “Potential Role of Uric Acid in Sickle Cell Nephropathy” 9th Annual Sickle Cell Disease Research and Educational Symposium, April 2015.

5. “Effects of Hydroxyurea on Cerebral Blood Flow Velocity in Sickle Cell Anemia: Results from the BABY HUG Trial. 9th Annual Sickle Cell Disease Research and Educational Symposium, April 2015.

6. “Outcomes of Referrals for Mild and Moderate Thrombocytopenia” American Society of Hematology Annual Meeting. December 2015. 126:41

7. “Impact of Sickle Cell Therapies on Growth Patterns” American Society of Hematology Annual Meeting. December 2017.

8. “Impact of Hyperfiltration during Early Childhood on the Natural History of Albuminuria in Pediatric Sickle Cell Anemia.” American Society of Hematology Annual Meeting. December 2018.

9. “A multicenter, open-label, randomized, Phase II study evaluating the effect of crizanlizumab plus standard of care versus standard of care alone on renal function in patients with sickle cell disease and chronic kidney disease (STEADFAST)” SCDAA Annual Meeting. October 2019

**POSTER EXHIBITS**

1. “Elective Cholecystectomy Decreases the Morbidity of Cholelithiasis and Cholecystectomy in Pediatric Sickle Cell Disease” American Society of Hematology Annual Meeting Dec 2009. *Blood* 2009 114:1544
2. “Hydroxyurea Treatment in Children with HbSC Disease and HbSb+ thalassemia” 4th Annual Sickle Cell Disease Research and Educational Symposium, Feb 2010.
3. “Finding Brain MRI Abnormalities in Patients with Sickle Cell Disease Based on Clinical Indication” 4th Annual Sickle Cell Disease Research and Educational Symposium, Feb 2010.
4. “Influence of Hemoglobin Level on Clinical Findings in Infants with Sickle Cell Anemia: Data from BABY HUG”. American Society of Hematology Annual Meeting Dec 2010; *Blood* 2010 116:1631
5. “Liver Histology, Liver Iron Concentration (LIC), and Serum Ferritin in a Large Cohort of Chronically Transfused Children with Sickle Cell Anemia: Limitations of LIC As a Marker for Hepatic Injury and Ferritin as An Indicator for Chelation Initiation” American Society of Hematology Annual Meeting, Dec 2011. *Blood* 2011 118:2142
6. “Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Anemia”. American Society of Hematology Annual Meeting Dec 2011; *Blood* 2011 118:3155
7. “2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study” American Society of Hematology Annual Meeting Dec 2012; *Blood* 2012 120:3212.
8. “The Process of Acquiring Health Education for First Time Parents of an Infant with Sickle Cell Disease” American Society of Hematology Annual Meeting Dec 2012; *Blood* 2012 120:4282.
9. “Relationships between Executive Functions and Social Skills in Children with Pediatric Sickle Cell Disease.” Annual Meeting of the American Psychological Association 2013.
10. “Executive Functions and Social Skills in Pediatric Sickle Cell Disease: With and Without History of Silent Cerebral Infarct.” National Conference in Pediatric Psychology 2013.
11. “The Relationship between Executive Functioning and Social Skills in Children with Sickle Cell Disease and Childhood Brain Tumors.” National Conference in Pediatric Psychology 2013.
12. “Maintaining High Level of Care at Outreach Sickle Cell Clinics.” American Society of Hematology Annual Meeting Dec 2013; Blood 2013 122:2976
13. “A Systematic Review Of All Interventional Sickle Cell Trials Registered At Clinicaltrials.Gov.” American Society of Hematology Annual Meeting Dec 2013; Blood 2013 122:2990
14. “Encephaloduroarteriosynangiosis (EDAS) For Patients with Sickle Cell Disease.” American Society of Hematology Annual Meeting Dec 2013; Blood 2013 122:999
15. “Unique Case of Scurvy Masquerading as a Treatment Related Secondary Malignancy.” American Society of Pediatric Hematology Oncology May 2014. *Pediatric Blood and Cancer* June 2014 S19.
16. "Simultaneous determination of Free Heme and Free Hemoglobin in biological samples by Spectral Deconvolution”.” American Society of Hematology Annual Meeting Dec 2014; Blood 2014 124:4868

19. “Hematologic Effects of Hydroxyurea Treatment in Children with Hb SC and SB+ Thalassemia.” American Society of Hematology Annual Meeting Dec 2014; Blood 2014 124:4077.

20. “Chronobiology of Hypertension in Sickle Cell Disease.” American Society of Hematology Annual Meeting Dec 2014; Blood 2014 124:4094;

21. “Epidural Hematomas: A Case Series of this Rare Complication Associated with Sickle Cell Disease” 9th Annual Sickle Cell Disease Research and Educational Symposium, April 2015

22. “Effects of Hydroxyurea on Cerebral Blood Flow Velocity in Sickle Cell Anemia: Results from the BABY HUG Trial” 9th Annual Sickle Cell Disease Research and Educational Symposium, April 2015.

23. “ITP as an Extra-intestinal Manifestation of Ulcerative Colitis”. American Society of Pediatric Hematology Annual Meeting, May 2015; Pediatric Blood and Cancer June 2015

24. “Measurement of Free Hemin and Hemoglobin in Biological Matrices” Society for Free

 Radical Biology Meeting” November 2015

25. “Acute Kidney Injury is Prevalent during Pediatric Admissions for Acute Chest Syndrome”

 American Society of Hematology Annual Meeting. December 2015. 126:3403

26. “[Management of Severe Chronic Pain with Methadone in Pediatric Patients with Sickle Cell
 Disease](https://ash.confex.com/ash/2016/webprogram/Paper95130.html)” American Society of Hematology Annual Meeting. December 2016. 128:3663

27. “[Severe Anemia as an Early Predictor of Kidney Injury](https://ash.confex.com/ash/2016/webprogram/Paper91347.html). American Society of Hematology

 Annual Meeting. December 2016. 128:3670

28. Therapy Preference and Outcomes of Hydroxyurea for Pediatric Patients with Silent Cerebral

 Infarcts. American Society of Hematology Annual Meeting. December 2016. 128:3531

29. [Acute Kidney Injury during Pediatric Vaso-Occlusive Crisis](https://ash.confex.com/ash/2016/webprogram/Paper91336.html). American Society of

 Hematology Annual Meeting. December 2016. 128:3669

30. “Outcomes of Fever in Infants and Young Children with SCD Presenting to the Emergency

 Department” American Society of Hematology Annual Meeting. December 2016.128:3591

31. “[Malignancy Risk Markers in a Cohort of Referrals for Lymphadenopathy; An Evaluation of](https://ash.confex.com/ash/2016/webprogram/Paper97702.html)

[Clinical Features Including Lymph Node Size](https://ash.confex.com/ash/2016/webprogram/Paper97702.html)” American Society of Hematology Annual Meeting. December 2016. 128:2385

32. “Clinical Features and Outcomes of Pediatric Patients with May-Thurner Syndrome”

 American Society of Pediatric Hematology Oncology Annual Meeting. May 2017.

33. “Impact of Early Analgesia on Hospitalization for Sickle Cell Pain Crisis” American Society of Hematology Annual Meeting. December 2017.

34. “Acute Kidney Injury During Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease”. American Society of Pediatric Hematology Oncology May 2018.

35. “Impact of Exchange Transfusion and Depletion Exchange Transfusion on Iron Overload and Chelation Therapy for Sickle Cell Patients on Chronic Transfusion Therapy.” Sickle Cell Disease Association of America Annual Scientific Meeting. June 2018.

36. “Hydroxyurea Prevents Onset and Progression of Albuminuria in Children with Sickle Cell Anemia”. American Society of Nephrology Annual Meeting. October 2018.

37. “Children with Sickle Cell Anemia and APOL1 Gene Variants Develop Albuminuria Early in Life.” American Society of Hematology Annual Meeting. December 2018.

38. “Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing.” American Society of Hematology Annual Meeting. December 2018.

39. “Injustice and Catastrophizing in the Sickle Cell Disease Dyad”. Annual Meeting and Scientific Sessions of the Society of Behavioral Medicine. March 2019.

40. “Adverse Childhood Experiences are Linked to Increased Morbidity in Children with Sickle Cell Anemia” American Society of Pediatric Hematology Oncology Annual Meeting. May 2019.

41. “Nocturnal Hypoxemia Measured by Polysomnogram Is Associated with Acute Chest Syndrome in a Pediatric Sickle Cell Disease Population.” American Thoracic Society International Conference. May 2019.

42. The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST). American Society of Hematology Annual Meeting. December 2019.

43. The Impact of Different Pediatric Estimated GFR Equations on Reporting of Renal Outcomes. American Society of Hematology Annual Meeting. December 2019.

44. Impact of a Pediatric Sickle Cell Outpatient Pain Clinic on Health Outcomes. American Society of Hematology Annual Meeting. December 2019.

45. Predictors of Social Skills in Youth with Sickle Cell: Parent Measures and Child Executive Function. American Psychology Association Annual Meeting. August 2020.

46. Development of a genetic risk score for albuminuria in sickle cell patients. American Society of Human Genetics. October 2020.

 Received “Reviewers’ Choice” Award for top 10% abstract.

**Mentorship Portfolio**

| Abstracts, Manuscripts and Awards Completed by Dr. Lebensburger’s Mentees |
| --- |
| Trainee (Position) | Year(s) of Mentorship | Abstract  | Publications During Mentorship (Authors, Title Journal PMID) | Award |
| Emily Goodwin, MD(H/O Fellow) | 2009-2010 | ASH Annual Meeting *Blood* 2009 114:1544 | Goodwin, Paige, **Lebensburger**, Fineburg, Howard. Elective Cholecystectomy Reduces Morbidity of Cholelithiasis in Pediatric Sickle Cell Disease. *Pediatric Blood Cancer*. July 2016 |  |
| Christina Bemrich Stolz MD MSPH(H/O Fellow) | 2010-2012 | ASH Annual Meeting Blood 2011 118:3155  | Bemrich-Stolz CJ, Halanych JH, Howard TH, Hilliard LM, **Lebensburger** JD. Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease *Int J Hem* 2015 PMID: 26900602 |  |
| Stephen Johnson MSIII (Medical Student) | 2011 |  | **Lebensburger J,** Johnson SM, Askenazi D et al. “Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.” Am J Hematol. 2011 MayPMID: 21523807 |  |
| Nigel Rozario MPH (MPH Student) | 2011 |  | **Lebensburger J,** Johnson SM, Askenazi D et al. “Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.” Am J Hematol. 2011 MayPMID: 21523807 |  |
| Erika Vogel Smith MD(Pediatric Resident) | 2011-2012 | ASH Annual Meeting *Blood* 2011 118:2142 | Vogel Smith, E, **Lebensburger, JD**, Hilliard., et al. “Ferritin and Liver Iron Concentration in Predicting Liver Histology in Children with Sickle Cell on Chronic Transfusion”. *Journal of Pediatr Gastroenterology and Nutrition*. 2014 Mar; PMID: 24553473 |  |
| Michael Gleason MD MSPH (Hem Onc Fellow) | 2011-2013 | American Society of Pediatric Hematology Oncology Annual Meeting 2014 |  |  |
| Courtney Williams MPH (MPH Student) | 2013 | National Sickle Cell Disease Research Symposium | Williams, C., Hogan Smith, C, Osborn, K., Bemrich-Stolz, C., Hilliard, L., Howard, T., **Lebensburger, JD**. Patient Centered Approach to Designing Sickle Cell Transition Education. *Journal of Pediatric Hematology Oncology.* 2015 PMID:24807007 | Charles Barkley Health Disparities Investigator Award.  |
| Jennifer Hamm MD (Hem Onc Fellow) | 2013-2016 | ASH Annual Meeting. 1) Blood 2013 122:2976 2) Blood 2014 124:4868 | Hamm, J., Hilliard, L., Howard, T., **Lebensburger, J**. “Maintaining High Level of Care at Satellite Sickle Cell Clinics. *Journal of Health Care for the Poor and Underserved.* 2016 Feb 27(1):280-292. PMID:27763470Hamm, J., Rathore, N., Lee, P., LeBlanc, Z., **Lebensburger, J**., Meier, E., Kwiatkowski, J. Cranial Epidual Hematomas: A Case Series and Literature Review. *Pediatric Blood and Cancer.* 2017 Mar;64(3). PMID: 27618802Oh, J., Hamm, J. Xu, X., Genschmer, K., **Lebensburger, J**., Marques, M., Kerby, J., Pittet, J., Gaggar, A., Zhong, M. Patel, R. Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices. Redox Biology. Accept August 2016. | 1) UAB Pediatric Subspecialty Research Achievement Award. 2) ASH Research Training Award for Fellows, Finalist, 2015. 3) Dixon Fellowship Award.  |
| Rakesh Patel MPH(MPH Student) | 2014 | ASH Annual Meeting, Blood 2014 124:4077 | **Lebensburger, JD**., Patel, RJ., Palabindela, et al. Hydroxyurea Decreases Hospitalizations in Pediatric Patients with HbSC and Hb SB+ Thalassemia. *Journal of Blood Medicine*. 2015 Dec 15;6:285-90. PMID: 26719735. | ASH Abstract Achievement Award ($500) |
| Hannah Ware MS I (Med Student) | 2014 | Oral presentation, ASH Annual Meeting Blood 2014 124:440 |  | ASH Abstract Achievement Award ($500) |
| Charles Schlappi MD (Peds Resident) | 2015-Present | Oral presentation, ASH Annual Meeting, Dec 2015. *Blood 2015 126:4* | Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, **Lebensburger** J. Outcomes in Mild to Moderate Isolated Thrombocytopenia. *Pediatrics*. 2018 June 11.PMID:29891565.Schlappi C, Bernstock JD, Ricketts W, Nix GA, Poole C, Lebensburger J, Friedman GK. [Roseamonas gilardii Bacteremia in a Patient With HbSβ0-thalassemia: Clinical Implications and Literature Review.](https://www.ncbi.nlm.nih.gov/pubmed/30951022) J Pediatr Hematol Oncol. 2019 Apr 3. PMID: 30951022 | ASH Abstract Achievement Award ($500) |
| Prasannalaxmi Palabindela MBBS (Med Student) | 2015-2016 | ASH Annual Meeting, Dec 2015. *Blood 2015 126:3403.* *Blood 2015 126:41* | **Lebensburger, JD**., Patel, RJ., Palabindela, et al. Hydroxyurea Decreases Hospitalizations in Pediatric Patients with HbSC and Hb SB+ Thalassemia. *Journal of Blood Medicine*. 2015 Dec 15;6:285-90. PMID: 26719735.Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, **Lebensburger** J. Outcomes in Mild to Moderate Isolated Thrombocytopenia. *Pediatrics*. 2018 June 11.PMID:29891565 | ASH Abstract Achievement Award ($500) |
| David McCall MD (Peds Resident) | 2015-2017 |  1) ASPHO Annual Meeting, May 20162) Southern Society for Pediatric Research March 2016 | Nagalapuram, V., McCall, D., Palabindela, P., Howard, T., Bemrich-Stolz, C., **Lebensburger, J**., Hilliard, L., Wilson, H. Outcomes of Isolated Neutropenia Referred to Pediatric Hematology Oncology Clinic*. Pediatrics*. Accepted July 2020 |  |
| Jennifer McDaniel MD (H/O Fellow) | 2015-2017 |  |  | 1) Dixon Fellowship Award2) HTRS Mentored Career Development Award |
| Sujatha Baddam MBBS (Med Student)  | 2016-Present | ASH Annual Meeting, Dec 2016. *Blood 2016 128:3669 and 128:3670*SCDAA Annual Meeting 2018 | Aban, I., Baddam, S., Hilliard, L., Howard, T., Feig, D., **Lebensburger J**., “Severe Anemia Early in Life as a Risk Factor for Sickle Cell Kidney Disease.” *Blood*. Accept November 2016. PMID:27919909Baddam, S., Aban, I., Hilliard, L., Howard, T., Askenazi, D., **Lebensburger J**. “Acute Kidney Injury During Pediatric Sickle Cell Vas0-Occlusive Pain Crisis”. *Pediatric Nephrology*.2017 Aug 32 (8) 1451-1456.S. Baddam, Cutter, G., Wolfson, J., Friedman, G. **Lebensburger, J**. "Publication Outcomes of Abstracts from the American Society of Hematology Annual Meeting". *American Journal of Hematology* 2017 May 92(5) |  |
| Tulia Rushton MSIII (Med Student) | 2016-2018 | ASH Annual Meeting, Dec 2016. *Blood 2016 128:3531* | Rushton, T., Aban, I., Young, D., Hilliard, L. Howard, T. **Lebensburger,** J., “Hydroxycarbamide for Sickle Cell Patients with Silent Cerebral Infarcts: Outcomes and Patient Preference.” *British Journal of Haematology*. 2018 April 181 (1) 145-148 | ASH Abstract Award |
| Krishnaveni Sirrigadi MBBS (Med Student) | 2016-Present | ASH Annual Meeting, Dec 2016. *Blood 2016 128:3591* | Krishnaveni Sirigaddi MBBS, Inmaculada Aban, PhD, Amelia Jantz, CRNP, Brandi M. Pernell DNP, Lee M. Hilliard, MD, Smita Bhatia MD, **Jeffrey D Lebensburger DO MSPH**. Outcomes of Febrile Events in Pediatric Patients with Sickle Cell Anemia. *Pediatric Blood and Cancer*. Accept July 30 2018. |  |
| Crystal Taylor (PhD Candidate) | 2016-Present |  |  |  |
| Orlando Esparza MD (Peds Resident) | 2016-Present | American Society of Hematology Annual Meeting, Dec 2016. *Blood 2016 128:2385* | Publication Submitted |  |
| Melanie Fields MD, Instructor. Washington University | 2016-2017.ASH CRTI Mentor |  |  | 1) NHLBI K23 2) ASH Scholar |
| Zach LeBlancPediatric H/O Instructor | 2014-2016 | ASH Annual Meeting 2016 128:3663 | Leblanc, Z., Vance, C., Payne, J., Zhang, Jie, Hilliard, L., **Lebensburger, J**, Howard, T. “Management of Severe Chronic Pain with Methadone in Pediatric Patients with Sickle Cell Disease.” *Pediatric Blood and Cancer*. Accept March, 2018Hamm, J., Rathore, N., Lee, P., LeBlanc, Z., **Lebensburger, J**., Meier, E., Kwiatkowski, J. Cranial Epidual Hematomas: A Case Series and Literature Review. *Pediatric Blood and Cancer.* 2017 Mar;64(3). PMID: 27618802 |  |
| Anna Hoppmann MD. (Peds Resident) | 2016-present | ASPHO Abstract. *Pediatric Blood and Cancer* Vol 64 2017 |  |  |
| Jason Payne MD(Peds Fellow) | 2016-present | ASH Annual Meeting, Dec 2017.SCDAA Annual Meeting 2018 | Leblanc, Z., Vance, C., Payne, J., Zhang, Jie, Hilliard, L., **Lebensburger, J**, Howard, T. “Management of Severe Chronic Pain with Methadone in Pediatric Patients with Sickle Cell Disease.” *Pediatric Blood and Cancer*. Accept March, 2018Jason Payne, MD, Inmaculada Aban, PhD, Lee M. Hilliard, MD,Jennifer Madison, CPhT, Christina Bemrich-Stolz, MD, MSPH, Thomas H Howard, MD, Amanda Brandow, DO, MS, Emily Waite, PharmD, **Jeffrey D Lebensburger, DO, MSPH**. Impact of Early Analgesia on Hospitalization Outcomes for Sickle Cell Pain Crisis. *Pediatric Blood and Cancer*. Accept July 30 2018 | Hematology Fellow Consortium |
| Jamie Oakley MD (Peds Resident) | 2017-present | ASPHO Abstract 2018 | Oakley J, Zahr R, Aban I, Kulkarni V, Patel RP, Hurwitz J, Askenazi D, Hankins J, **Lebensburger** J. Acute Kidney Injury During Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease. *American Journal of Hematology* 2018 May 14 PMID: 29756409 |  |
| Cecelia Calhoun MD, Washington University | 2017-2018ASH CRTI mentor |  |  | ASH CRTI |
| Varsha Kulkarni MBBS (SCD Research Intern | 2017-present | Oral presentation, ASH Annual Meeting, Dec 2017. | Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, **Lebensburger** J. Outcomes in Mild to Moderate Isolated Thrombocytopenia. *Pediatrics*. 2018 June 11.PMID:29891565Oakley J, Zahr R, Aban I, Kulkarni V, Patel RP, Hurwitz J, Askenazi D, Hankins J, **Lebensburger** J. Acute Kidney Injury During Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease. *American Journal of Hematology* 2018 May 14 PMID: 29756409 |  |
| Rima Zahr DOPediatric Nephrologist. UT/St. Jude | 2017-present | ASPHO abstract 2018ASN abstract 2018ASH abstract 2018 | Oakley J, Zahr R, Aban I, Kulkarni V, Patel RP, Hurwitz J, Askenazi D, Hankins J, **Lebensburger** J. Acute Kidney Injury During Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease. *American Journal of Hematology* 2018 May 14 PMID: 29756409Zahr RS, Hankins JS, Kang G, Li C, Wang WC, **Lebensburger** J, Estepp JH. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Am J Hematol. 2019 Jan;94(1):E27-E29 |  |
| Julia Ramos MD, PhD. UCSF.  | 2018- present. CRTI Mentee |  |  | ASH CRTI |
| Seth Karol MD. St Jude  | 2018-presentCRTI Mentee |  |  | NIH/NCI. K08 Mentored Career Development Award |
| Brandi Pernell DNP  | 2018- present. Peds H/O faculty | ASPHO Abstract 2018 |  | Deep South Mentored Career Development Program (KL2 Scholars) |
| Vishu Nagalapuram , MBBS | 2018-2019SCD Research Intern |  | Nagalapuram V, Kulkarni V, Leach J, Aban I, Sirigaddi K, Lebensburger JD, Iyer P. [Effect of Sickle Cell Anemia Therapies on the Natural History of Growth and Puberty Patterns.](https://www.ncbi.nlm.nih.gov/pubmed/30951025) J Pediatr Hematol Oncol. 2019 Apr 3. PMID: 30951025 |  |
| Donna Murdaugh, PhD | 2018- present. Peds H/O faculty | ASPHO Abstract 2018 |  | Deep South Mentored Career Development Program (KL2 Scholars) |
| Suraj Hande | 2019-2020SCD Research Intern |  | [Malgorzata Kasztan](https://pubmed.ncbi.nlm.nih.gov/?term=Kasztan+M&cauthor_id=31951651), [Inmaculada Aban](https://pubmed.ncbi.nlm.nih.gov/?term=Aban+I&cauthor_id=31951651), [Suraj P Hande](https://pubmed.ncbi.nlm.nih.gov/?term=Hande+SP&cauthor_id=31951651), [David M Pollock](https://pubmed.ncbi.nlm.nih.gov/?term=Pollock+DM&cauthor_id=31951651), [Jeffrey D Lebensburger](https://pubmed.ncbi.nlm.nih.gov/?term=Lebensburger+JD&cauthor_id=31951651) Sex Differences in the Trajectory of Glomerular Filtration Rate in Pediatric and Murine Sickle Cell Anemia. Blood Advances. 2020 Jan 28; 4(2) 263-25 PMID: 31951651 |  |
| Marcus Carden, MD. UNC  | 2019-2020 |  |  | ASH CRTI  |
| Regina Myers, MD. CHOP | 2019-2020 |  |  | ASH CRTI  |
| Sarah Shaner, MSI UAB | 2020 | Abstract submitted to ASH |  | NIH/NHLBI. T35HL007473Short Term Training in Health Professional Schools |
| Hope Wilson, UAB Faculty | 2019- |  | Nagalapuram, V., McCall, D., Palabindela, P., Howard, T., Bemrich-Stolz, C., **Lebensburger, J**., Hilliard, L., Wilson, H. Outcomes of Isolated Neutropenia Referred to Pediatric Hematology Oncology Clinic*. Pediatrics* | ASH CRTINIH Diversity Grant pending administrative review. |
| Raven Myrick, CRNP | 2019-2020 |  | Myrick R, Blakemore S, Waite E, Pernell B, Madan-Swain A, Hilliard L, **Lebensburger J\***. Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes. *Pediatric Blood and Cancer*. 2020 Aug 15. PMID:32798305 |  |